Deal funds clinical development of HS-110, HS-410, corporate purposes
By Devika Patel
Knoxville, Tenn., July 24 - Heat Biologics, Inc. said it priced its $25 million initial public offering of stock with a $3.75 million greenshoe. The deal was announced June 28.
The company will sell 2.5 million common shares at $10.00 per share.
Settlement is expected July 29.
Aegis Capital Corp. is the bookrunning manager.
Proceeds will be used for clinical development of HS-110 and HS-410 and for other general corporate purposes.
The biopharmaceutical company is based in Chapel Hill, N.C. It expects its shares to trade on the Nasdaq under the symbol "HTBX."
| Issuer: | Heat Biologics, Inc.
|
| Issue: | Common stock
|
| Amount: | $25 million
|
| Greenshoe: | $3.75 million
|
| Shares: | 2.5 million
|
| Price: | $10.00
|
| Warrants: | No
|
| Bookrunner: | Aegis Capital Corp.
|
| Co-manager: | Cantor Fitzgerald & Co.
|
| Announcement date: | June 28
|
| Pricing date: | July 24
|
| Settlement date: | July 29
|
| Stock exchange: | Nasdaq: HTBX
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
